In the field of Assisted Reproductive Technology (ART), the need for optimizing embryo selection to maximize the chances of a successful pregnancy has long been the focal point. Genetic testing, has helped over the years in screening embryos for chromosomal abnormalities. These abnormalities could lead to miscarriages, recurrent implantation failure or abnormalities in the resulting baby. This testing has been previously achieved with the aid of a procedure known as Pre-implantation Genetic Testing. This is done by taking some parts (cells) of the embryos and screening for these abnormalities, a process known as embryo biopsy, however there has been some concerns on its invasive approach. In recent times, with advancement in technology, a non-invasive approach has been made available for the screening of embryos for chromosomal abnormalities. Non- Invasive Pre-implantation Genetic Testing for Aneuploidy (NIPGT-A) represents an important landmark and advancement in the field of ART. It offers a non-invasive and highly accurate method of assessing chromosomal abnormalities in embryos. 

This article delves into the innovative applications and potential impact of NIPGT-A in ART procedures.

Understanding NIPGT-A for Embryos:

NIPGT-A involves the analysis of the cell-free DNA from the embryo culture medium which is released by the embryo during development, in vitro. This non-intrusive and non-invasive approach eliminates the need for embryo biopsy, an invasive and potentially risky to embryo viability and implantation potential if not done by trained/experienced personnel. By analysing the genetic material released by embryos, NIPGT-A provides valuable revelations on the chromosomal make-up of the embryo; identifying the presence or absence of abnormalities without compromising the embryo’s viability.

Precision and Accuracy:

One of the key advantages of NIPGT-A for embryos lies in its precision and accuracy. By analysing a comprehensive panel of chromosomal abnormalities, NIPGT-A enables embryologists to identify normal (euploid) embryos i.e with the correct number of chromosomes. This ensures the selection of embryos with the highest implantation potential and further reducing the risk of miscarriage or chromosomally abnormal pregnancies and improves the chances of healthy live birth.

Clinical Applications and Benefits:

NIPGT-A holds significant promise for improving the success rates of ART procedures. By selecting normal (Euploid) embryos for transfer, we can increase the likelihood of achieving a healthy pregnancy while minimizing the risk of chromosomal disorders, e.g Down syndrome. Also, Non-invasive PGT-A may provide a less complicated and less costly approach to pre-implantation genetic testing of aneuploidy (PGT-A). It can winnow out false myths related with genetic testing, as many believe that the invasive PGT-A would compromise the development of the foetus eventually.

NIPGT-A in NORDICA:

At Nordica Fertility Center being the pioneering fertility clinic in Nigeria, we are proud to offer Non-Invasive Pre-implantation Genetic Testing for Aneuploidies (NIPGT-A). It is a revolutionary service in Assisted Reproductive Technology. As the first clinic in Nigeria validated to perform this procedure, we are committed to providing our patients with cutting-edge solutions for achieving their dream of parenthood. With our expertise and advanced technology, we deliver accurate NIPGT-A results ensuring swift and reliable insights into embryo chromosomal abnormalities, we believe this is a right step in the right direction of fulfilling our mantra “WE COMPLETE FAMILIES”